Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anita Vedel Christiansen"'
Autor:
Inge Marie Svane, Santosh M. Nair, Igor Puzanov, Caroline Robert, Jessica Cecile Hassel, Shahneen Sandhu, Anita Vedel Christiansen, Kath Lowery, Kristine Pemberton, Mohammad Al Hajj, Scott J. Diede, Eva Ehrnrooth, Alexander M. Eggermont
Publikováno v:
Journal of Clinical Oncology. 40:TPS9589-TPS9589
TPS9589 Background: The treatment of melanoma has improved markedly with the emergence of new immune therapies, and both anti-PD-1 monotherapy and the combination of the anti-PD-1 antibody nivolumab and anti-CTLA-4 therapy ipilimumab are now consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4323639b2a1d3c1728923bdf5ece663d
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9589
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9589
Autor:
Afshin Salsali, Thomas Meinicke, Flavien Roux, Uli C. Broedl, Hans-Ulrich Haering, Ludwig Merker, Hans-Juergen Woerle, G. Kim, Anita Vedel Christiansen
Publikováno v:
Diabetes Research and Clinical Practice. 110:82-90
This study investigated the long-term efficacy and safety of empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes mellitus (T2DM). Of 666 patients treated with empagliflozin 10 mg, empagliflozin 25 mg or placebo on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::affcfec3ff9aa0ab1feb2bf0985e63d8
https://doi.org/10.1016/j.diabres.2015.05.044
https://doi.org/10.1016/j.diabres.2015.05.044
Autor:
Thomas Meinicke, Flavien Roux, HU Häring, Hans-Juergen Woerle, G. Kim, Afshin Salsali, Ludwig Merker, Anita Vedel Christiansen, Uli C. Broedl
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association. 32(12)
Aims To investigate the long-term efficacy and safety of empagliflozin as add-on to metformin in people with Type 2 diabetes. Methods Of 637 participants treated with empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily for 24 weeks, 463 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7218e4e54ea5c5b1bf0e24b69594392e
https://pubmed.ncbi.nlm.nih.gov/26031566
https://pubmed.ncbi.nlm.nih.gov/26031566
Autor:
Christopher S. Kovacs, Afshin Salsali, Flavien Roux, Uli C. Broedl, Anita Vedel Christiansen, Hans-Juergen Woerle, Peter Stella, Ludwig Merker, G. Kim, Veeraswamy Seshiah
Publikováno v:
Clinical therapeutics. 37(8)
To investigate the long-term efficacy and safety of empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus.Of 498 patients randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d7b631987998f18ff147e715521b9cb
https://pubmed.ncbi.nlm.nih.gov/26138864
https://pubmed.ncbi.nlm.nih.gov/26138864
Autor:
Sam Schulman, Ajay K. Kakkar, Eriksson Henry, Samuel Z. Goldhaber, Janet Schnee, Clive Kearon, Sebastian Schellong, Patrick Mismetti, Anita Vedel Christiansen
Publikováno v:
Blood. 118:205-205
Abstract 205 Background: Dabigatran has been compared with warfarin for treatment of acute venous thromboembolism in one previous trial (RE-COVER). Based on the low rate of the primary outcome as the RE-COVER study was running, we undertook this repl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1b3254d220f73a1c8868cfd4b6b8f50
https://doi.org/10.1182/blood.v118.21.205.205
https://doi.org/10.1182/blood.v118.21.205.205
Autor:
Cornelis N. van Dijk, Rohan Hettiarachchi, Harry R. Büller, Andreas A. Kurth, Janet Schnee, Stefan Hantel, Nadia Rosencher, Ola E. Dahl, Simon P. Frostick, Bengt I. Eriksson, Anita Vedel Christiansen
Publikováno v:
Blood. 108:573-573
BACKGROUND: Oral DVT prophylaxis not requiring monitoring is an advantage in orthopaedic patients. Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolic events (VTE) following orth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::022443224d55971cb5473376fb54be17
https://doi.org/10.1182/blood.v108.11.573.573
https://doi.org/10.1182/blood.v108.11.573.573
Autor:
Peter Stella, Flavien Roux, Ludwig Merker, Uli C. Broedl, Hans-Juergen Woerle, Michael Roden, G. Kim, Anita Vedel Christiansen, Afshin Salsali
Publikováno v:
Cardiovascular diabetology, 14:154
Cardiovascular Diabetology
Cardiovascular Diabetology
Background To investigate the long-term efficacy and safety of empagliflozin monotherapy compared with placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus. Methods Of 899 patients randomized to receive empagliflozin 10 mg, e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31541edd8e84a4b86caef2e14bd652ff